Caribou Biosciences Inc (NASDAQ: CRBU) open the trading on Wednesday, with a bit cautious approach as it glided -3.23% to $1.20, before settling in for the price of $1.24 at the close. Taking a more long-term approach, CRBU posted a 52-week range of $1.20-$8.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 71.11% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -37.16%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -20.17%. This publicly-traded company’s shares outstanding now amounts to $90.55 million, simultaneously with a float of $79.17 million. The organization now has a market capitalization sitting at $108.67 million. At the time of writing, stock’s 50-day Moving Average stood at $1.5450, while the 200-day Moving Average is $2.0064.
Caribou Biosciences Inc (CRBU) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Caribou Biosciences Inc’s current insider ownership accounts for 12.58%, in contrast to 60.03% institutional ownership. According to the most recent insider trade that took place on Feb 21 ’25, this organization’s Chief Legal Officer sold 3,564 shares at the rate of 1.35, making the entire transaction reach 4,811 in total value, affecting insider ownership by 443,502. Preceding that transaction, on Feb 21 ’25, Company’s Chief Business Officer sold 3,564 for 1.35, making the whole transaction’s value amount to 4,811. This particular insider is now the holder of 66,936 in total.
Caribou Biosciences Inc (CRBU) Earnings and Revenue Records
Caribou Biosciences Inc’s EPS decrease for this current 12-month fiscal period is -20.17% and is forecasted to reach -1.86 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -12.22% through the next 5 years, which can be compared against the -37.16% growth it accomplished over the previous five years trading on the market.
Caribou Biosciences Inc (NASDAQ: CRBU) Trading Performance Indicators
Let’s observe the current performance indicators for Caribou Biosciences Inc (CRBU). It’s Quick Ratio in the last reported quarter now stands at 7.38. The Stock has managed to achieve an average true range (ATR) of 0.10. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 9.47.
In the same vein, CRBU’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.65, a figure that is expected to reach -0.42 in the next quarter, and analysts are predicting that it will be -1.86 at the market close of one year from today.
Technical Analysis of Caribou Biosciences Inc (CRBU)
[Caribou Biosciences Inc, CRBU] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 16.44% While, its Average True Range was 0.0921.
Raw Stochastic average of Caribou Biosciences Inc (CRBU) in the period of the previous 100 days is set at 1.40%, which indicates a major fall in contrast to 8.08% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 52.55% that was lower than 72.79% volatility it exhibited in the past 100-days period.
